NextCure, Inc.
NXTCHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, NextCure, Inc. focuses on Biotechnology services and products. NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. Valued at $20.8M, NXTC is a micro-cap name in its sector. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors.
Market Cap
$20.8M
Beta
1.42
P/E (TTM)
—
P/E (Fwd)
-0.72
EPS (TTM)
$-15.63
EPS (Fwd)
$-7.07
ROE
-132.4%
ROA
-66.7%
Cash
$29.7M
Total Debt
$4.9M
Free CF
-$29.2M
52W Change
3.9%
Annual Financials
Cash vs Debt
Where NXTC stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, NXTC finished 31.53% below its 150-day moving average ($9.61) and 31.17% below its 200-day moving average ($9.56). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NXTC overbought or oversold?
At the July 15, 2026 close, NXTC's RSI(14) was 88.6, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
NextCure, Inc. holds $29.7M in cash against $4.9M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$29.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -132.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing NXTC's risk profile alongside its fundamentals and technical indicators provides a more complete picture.